Berman Brian, Grada Ayman, Berman Daniela K
Dr. B. Berman is with the Department of Dermatology and Cutaneous Surgery at the University of Miami Miller School of Medicine in Miami, Florida, and the Center for Clinical and Cosmetic Research in Aventura, Florida.
Dr. Grada is with the Department of Dermatology at Case Western Reserve University School of Medicine in Cleveland, Ohio.
J Clin Aesthet Dermatol. 2022 Oct;15(10 Suppl 1):S3-S10.
Actinic keratosis (AK) is a chronic disease resulting from deleterious effects of long-term, cumulative, epidermal exposure to ultraviolet (UV) light. UV-induced mutations in p53, ras, and p16 genes lead to the emergence of abnormal epidermal actinic keratosis (AKs) cells, which proliferate while avoiding apoptosis and may lead to invasive squamous cell carcinoma. There are both lesion-targeted and field-directed topical treatments. This review is of new and emerging information on tirbanibulin and tirbanibulin 1% ointment, which is approved for topical field treatment of actinic keratosis on the face and scalp. Potent antiproliferative and proapoptotic activities result from tirbanibulin's inhibition tubulin polymerization and disruption of microtubule formation and Src kinase signaling. Tirbanibulin 1% ointment is an effective treatment of facial and scalp AK after five consecutive once-daily applications, as measured by complete and partial clearance and percent reduction in the number of lesions. Localized skin reactions are usually mild to moderate, resolving within a month. The short and well-tolerated course of therapy results in very high patient adherence to the treatment regimen.
光化性角化病（AK）是一种慢性疾病，由长期累积的表皮暴露于紫外线（UV）的有害影响所致。紫外线诱导的p53、ras和p16基因中的突变导致异常的表皮光化性角化病（AK）细胞出现，这些细胞增殖同时避免凋亡，并可能导致侵袭性鳞状细胞癌。有针对病变的和针对区域的局部治疗方法。本综述介绍了关于替尔泊肽和1%替尔泊肽软膏的新出现的信息，该软膏已被批准用于面部和头皮光化性角化病的局部区域治疗。替尔泊肽抑制微管蛋白聚合、破坏微管形成和Src激酶信号传导，从而产生强大的抗增殖和促凋亡活性。通过完全和部分清除以及病变数量减少百分比来衡量，连续每日一次应用五次后，1%替尔泊肽软膏是治疗面部和头皮AK的有效方法。局部皮肤反应通常为轻度至中度，在一个月内消退。疗程短且耐受性良好，导致患者对治疗方案的依从性非常高。
